Management of Persistent Atrial Fibrillation and HFrEF with Elevated NT-proBNP Despite SGLT2i Therapy
Continue empagliflozin (Jardiance) and optimize guideline-directed medical therapy (GDMT) by ensuring the patient is on maximal tolerated doses of ACE-I/ARB/ARNI, beta-blocker, and mineralocorticoid receptor antagonist (MRA), as this combination reduces mortality and hospitalization in HFrEF regardless of atrial fibrillation status. 1
Immediate Medication Optimization
Your patient's NT-proBNP of 1231 pg/mL after 6 months on empagliflozin indicates persistent symptomatic heart failure requiring intensification of therapy:
Core GDMT Components (Class I Recommendations)
ACE-I/ARB or ARNI: If on ACE-I/ARB and still symptomatic, strongly consider switching to sacubitril/valsartan, which provides additional mortality and hospitalization benefit beyond ACE-I alone 1
Beta-blocker: Ensure evidence-based beta-blocker (carvedilol, metoprolol succinate, or bisoprolol) is uptitrated to target or maximally tolerated dose 1
MRA (spironolactone or eplerenone): Add if not already prescribed, as this reduces mortality in symptomatic HFrEF 1
Continue empagliflozin: The SGLT2i benefit persists regardless of atrial fibrillation status, with consistent reductions in cardiovascular death and HF hospitalization 2, 3, 4
Atrial Fibrillation Rate Control Strategy
For persistent AF with HFrEF, prioritize rate control using beta-blockers as first-line therapy, with digoxin as reasonable add-on therapy if rate control remains inadequate. 5, 6, 5
Rate Control Approach:
- Beta-blocker is the preferred agent for rate control in HFrEF with AF (Class I recommendation) 5, 6, 5
- Avoid non-dihydropyridine calcium channel blockers (diltiazem, verapamil) as they worsen HF and increase hospitalization risk in HFrEF (Class III: Harm) 1
- Add digoxin if beta-blocker alone provides insufficient rate control (Class IIa) 5, 6, 5
- Assess exercise heart rate control and adjust medications to maintain physiological range during activity (Class I) 5, 6
Consider Rhythm Control:
If the patient remains symptomatic despite optimal rate control and GDMT, consider a rhythm-control strategy (cardioversion ± antiarrhythmic drugs or catheter ablation), as this is reasonable for chronic HF patients who remain symptomatic despite rate control (Class IIa) 5, 6, 5
Recent evidence suggests electrogram-anatomic guided catheter ablation provides superior long-term rhythm control and reduces cardiovascular events in persistent AF with HF 7
Prognostic Interpretation of NT-proBNP
An NT-proBNP of 1231 pg/mL indicates moderate-to-high residual risk despite SGLT2i therapy:
- NT-proBNP levels between 125-1000 pg/mL are associated with incremental risk, and your patient's level of 1231 pg/mL portends meaningful ongoing risk of HF hospitalization and death 8
- NT-proBNP offers much greater prognostic value than LVEF alone in patients on GDMT, making it the superior marker for risk stratification 8
- Empagliflozin reduces NT-proBNP levels over time, but persistent elevation signals need for further therapy optimization 9, 4
Additional Considerations
Anticoagulation:
Ensure appropriate oral anticoagulation for stroke prevention given chronic persistent AF (Class I recommendation) 10
Diuretic Management:
Optimize loop diuretic dosing based on volume status—diuretics improve symptoms and exercise capacity in congested patients (Class I) 1
Device Therapy Evaluation:
If LVEF remains ≤35% after ≥3 months of optimal medical therapy, evaluate for ICD and/or CRT eligibility based on QRS duration and morphology 1
Common Pitfalls to Avoid
- Do not discontinue empagliflozin based on elevated NT-proBNP alone—the drug provides consistent benefit in HFrEF with AF 3
- Do not use calcium channel blockers for rate control in HFrEF—they cause harm 1
- Do not accept suboptimal GDMT dosing—uptitrate all four medication classes (ARNI/ACE-I, beta-blocker, MRA, SGLT2i) to target doses
- Do not overlook rhythm control if symptoms persist despite adequate rate control and optimized GDMT 5, 6, 5